Saturday Feb 22
Just Released: "CardioNet, Inc. (BEAT) - Medical Equipment - Deals and Alliances Profile"
It carries out the development and marketing of mobile cardiac outpatient telemetry , which is used in the diagnosis and treatment of arrhythmias.
BioTelemetry Stock Rating Upgraded by Zacks
The firm currently has a $9.20 target price on the stock. Zacks ' price objective points to a potential upside of 5.99% from the company's current price.
BioTelemetry, Inc. to Release Fourth Quarter 2013 Earnings Results on February 26, 2014
BioTelemetry, Inc. will release its fourth quarter 2013 earnings on Wednesday, February 26, 2014 at 4:00 PM Eastern Time.
BIOTELEMETRY, INC. FILES (8-K) Disclosing Entry into a Material...
BIOTELEMETRY, INC. FILES Disclosing Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial Statements and Exhibits Item 1.01.